Wegovy's Real-World weight loss power tested in 500 korean patients
NCT ID NCT07280221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 500 Korean adults with obesity who are starting Wegovy (semaglutide) as part of their normal care. Researchers will track how much weight they lose and any side effects over about 52 weeks. The goal is to see how effective and safe the drug is in real-world clinics, not a controlled research setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Daejeon Endo Internal Medicine Clinic
Daejeon, 35220, South Korea